Literature DB >> 25029976

The Rare Diseases Clinical Research Network's organization and approach to observational research and health outcomes research.

Jeffrey P Krischer1, Rashmi Gopal-Srivastava, Stephen C Groft, David J Eckstein.   

Abstract

Established in 2003 by the Office of Rare Diseases Research (ORDR), in collaboration with several National Institutes of Health (NIH) Institutes/Centers, the Rare Diseases Clinical Research Network (RDCRN) consists of multiple clinical consortia conducting research in more than 200 rare diseases. The RDCRN supports longitudinal or natural history, pilot, Phase I, II, and III, case-control, cross-sectional, chart review, physician survey, bio-repository, and RDCRN Contact Registry (CR) studies. To date, there have been 24,684 participants enrolled on 120 studies from 446 sites worldwide. An additional 11,533 individuals participate in the CR. Through a central data management and coordinating center (DMCC), the RDCRN's platform for the conduct of observational research encompasses electronic case report forms, federated databases, and an online CR for epidemiological and survey research. An ORDR-governed data repository (through dbGaP, a database for genotype and phenotype information from the National Library of Medicine) has been created. DMCC coordinates with ORDR to register and upload study data to dbGaP for data sharing with the scientific community. The platform provided by the RDCRN DMCC has supported 128 studies, six of which were successfully conducted through the online CR, with 2,352 individuals accrued and a median enrollment time of just 2 months. The RDCRN has built a powerful suite of web-based tools that provide for integration of federated and online database support that can accommodate a large number of rare diseases on a global scale. RDCRN studies have made important advances in the diagnosis and treatment of rare diseases.

Entities:  

Mesh:

Year:  2014        PMID: 25029976      PMCID: PMC4124127          DOI: 10.1007/s11606-014-2894-x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  26 in total

1.  The Rare Diseases Clinical Research Network Contact Registry update: features and functionality.

Authors:  Rachel L Richesson; Rebecca Sutphen; Denise Shereff; Jeffrey P Krischer
Journal:  Contemp Clin Trials       Date:  2012-03-02       Impact factor: 2.226

2.  168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT).

Authors:  M M Reilly; M E Shy; F Muntoni; D Pareyson
Journal:  Neuromuscul Disord       Date:  2010-09-17       Impact factor: 4.296

3.  Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).

Authors:  Gunnar Tomasson; Maarten Boers; Michael Walsh; Michael LaValley; David Cuthbertson; Simon Carette; John C Davis; Gary S Hoffman; Nader A Khalidi; Carol A Langford; Carol A McAlear; W Joseph McCune; Paul A Monach; Philip Seo; Ulrich Specks; Robert Spiera; E William St Clair; John H Stone; Steven R Ytterberg; Peter A Merkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

4.  Rare disease research gets boost.

Authors:  Tracy Hampton
Journal:  JAMA       Date:  2006-06-28       Impact factor: 56.272

5.  Clinical severity and quality of life in children and adolescents with Rett syndrome.

Authors:  J B Lane; H-S Lee; L W Smith; P Cheng; A K Percy; D G Glaze; J L Neul; K J Motil; J O Barrish; S A Skinner; F Annese; L McNair; J Graham; O Khwaja; K Barnes; J P Krischer
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

Review 6.  An automated standardized system for managing adverse events in clinical research networks.

Authors:  Rachel L Richesson; Jamie F Malloy; Kathleen Paulus; David Cuthbertson; Jeffrey P Krischer
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Data standards for clinical research data collection forms: current status and challenges.

Authors:  Rachel L Richesson; Prakash Nadkarni
Journal:  J Am Med Inform Assoc       Date:  2011-05-01       Impact factor: 4.497

8.  Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.

Authors:  Joseph Pidala; Brenda Kurland; Xiaoyu Chai; Navneet Majhail; Daniel J Weisdorf; Steven Pavletic; Corey Cutler; David Jacobsohn; Jeanne Palmer; Sally Arai; Madan Jagasia; Stephanie J Lee
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

9.  Clinical research for rare disease: opportunities, challenges, and solutions.

Authors:  Robert C Griggs; Mark Batshaw; Mary Dunkle; Rashmi Gopal-Srivastava; Edward Kaye; Jeffrey Krischer; Tan Nguyen; Kathleen Paulus; Peter A Merkel
Journal:  Mol Genet Metab       Date:  2008-11-13       Impact factor: 4.797

10.  Achieving standardized medication data in clinical research studies: two approaches and applications for implementing RxNorm.

Authors:  Rachel L Richesson; Susan B Smith; Jamie Malloy; Jeffrey P Krischer
Journal:  J Med Syst       Date:  2009-04-03       Impact factor: 4.920

View more
  22 in total

Review 1.  National information system for rare diseases with an approach to data architecture: A systematic review.

Authors:  Simin Derayeh; Alireza Kazemi; Reza Rabiei; Azamossadat Hosseini; Hamid Moghaddasi
Journal:  Intractable Rare Dis Res       Date:  2018-08

Review 2.  Genomic medicine for kidney disease.

Authors:  Emily E Groopman; Hila Milo Rasouly; Ali G Gharavi
Journal:  Nat Rev Nephrol       Date:  2018-01-08       Impact factor: 28.314

3.  Multiple system atrophy: the case for an international collaborative effort.

Authors:  Lucy Norcliffe-Kaufmann; Jose-Alberto Palma; Florian Krismer
Journal:  Clin Auton Res       Date:  2015-04-11       Impact factor: 4.435

Review 4.  From promising molecules to orphan drugs: Early clinical drug development.

Authors:  Marc Dooms
Journal:  Intractable Rare Dis Res       Date:  2017-02

Review 5.  Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases.

Authors:  Carla Epps; Ralph Bax; Alysha Croker; Dionna Green; Andrea Gropman; Agnes V Klein; Hannah Landry; Anne Pariser; Marc Rosenman; Michiyo Sakiyama; Junko Sato; Kuntal Sen; Monique Stone; Fumi Takeuchi; Jonathan M Davis
Journal:  Ther Innov Regul Sci       Date:  2022-04-26       Impact factor: 1.337

Review 6.  Novel clinical trial design and analytic methods to tackle challenges in therapeutic development in rare diseases.

Authors:  Yimei Li; Rima Izem
Journal:  Ann Transl Med       Date:  2022-09

Review 7.  Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities.

Authors:  Jaime M Preussler; Lih-Wen Mau; Navneet S Majhail; Christa L Meyer; Ellen M Denzen; Kristen C Edsall; Stephanie H Farnia; Alicia Silver; Wael Saber; Linda J Burns; David J Vanness
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-14       Impact factor: 5.742

8.  Biomedical Data Sharing and Reuse: Attitudes and Practices of Clinical and Scientific Research Staff.

Authors:  Lisa M Federer; Ya-Ling Lu; Douglas J Joubert; Judith Welsh; Barbara Brandys
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

Review 9.  An overview of the impact of rare disease characteristics on research methodology.

Authors:  Danielle Whicher; Sarah Philbin; Naomi Aronson
Journal:  Orphanet J Rare Dis       Date:  2018-01-19       Impact factor: 4.123

10.  The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network.

Authors:  Peter A Merkel; Michele Manion; Rashmi Gopal-Srivastava; Stephen Groft; H A Jinnah; David Robertson; Jeffrey P Krischer
Journal:  Orphanet J Rare Dis       Date:  2016-05-18       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.